Neuroprotective effect of a dietary supplement against glutamate-induced excitotoxicity in retina.
HT-22 cells
glutamate-induced toxicity
pERK
retinal ganglion cells
Journal
International journal of ophthalmology
ISSN: 2222-3959
Titre abrégé: Int J Ophthalmol
Pays: China
ID NLM: 101553860
Informations de publication
Date de publication:
2019
2019
Historique:
received:
04
02
2019
accepted:
04
06
2019
entrez:
29
8
2019
pubmed:
29
8
2019
medline:
29
8
2019
Statut:
epublish
Résumé
To evaluate the neuroprotective effect of a dietary supplement (ClearVision EX We evaluated the protective effects CV on glutamate-induced cell toxicity of an immortalized mouse hippocampal cell line (HT-22) HT-22 cell death was induced by the addition of glutamate and co-incubation with CV protected against it. Oral administration of CV inhibited the decrease in scotopic threshold response amplitudes induced by the intravitreal injection of NMDA and those of the thickness of the inner retinal layer in the histological evaluation. The increased phosphorylated levels of extracellular signal-regulated kinase (ERK) but not cAMP response element binding protein (CREB) or Akt were observed 1h after NMDA injection in both the vehicle- and CV-treated rats; however, pERK activation was no more upregulated at 3h after NMDA injection. pERK upregulation was observed in Müller cells. CV shows a protective effect against both glutamate-induced HT-22 cell death and NMDA-induced retinal damage. pERK upregulation in the Müller cells plays a key role in the protective effect of CV against glutamate-induced retinal toxicity.
Identifiants
pubmed: 31456911
doi: 10.18240/ijo.2019.08.01
pii: ijo-12-08-1231
pmc: PMC6694051
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1231-1237Références
Tohoku J Exp Med. 1999 Mar;187(3):227-36
pubmed: 10458479
Curr Eye Res. 2002 Feb;24(2):114-22
pubmed: 12187483
Neuroreport. 2002 Nov 15;13(16):2103-7
pubmed: 12438934
Invest Ophthalmol Vis Sci. 2002 Dec;43(12):3744-53
pubmed: 12454046
Dev Neurobiol. 2007 Apr;67(5):603-16
pubmed: 17443811
Curr Opin Pharmacol. 2013 Feb;13(1):50-5
pubmed: 23069477
Cell Struct Funct. 2013;38(1):81-8
pubmed: 23485938
J Ophthalmol. 2013;2013:185825
pubmed: 24319591
Mol Ther. 2014 Aug;22(8):1434-1440
pubmed: 24821344
Exp Eye Res. 2015 Jan;130:29-37
pubmed: 25450059
Adv Exp Med Biol. 2015;803:581-96
pubmed: 25833529
Front Cell Neurosci. 2015 Mar 17;9:91
pubmed: 25852482
Biol Pharm Bull. 2015;38(11):1765-71
pubmed: 26521828
Biomed Res Int. 2015;2015:827516
pubmed: 26557702
Invest Ophthalmol Vis Sci. 2016 Feb;57(2):453-61
pubmed: 26868747
Sci Rep. 2016 Jun 08;6:27532
pubmed: 27270337
Eur J Pharmacol. 2016 Nov 15;791:213-220
pubmed: 27590359
Sci Rep. 2017 Jan 23;7:41210
pubmed: 28112267
Mol Med Rep. 2017 Apr;15(4):2179-2185
pubmed: 28260075
J Neurol Sci. 2017 Apr 15;375:355-359
pubmed: 28320167
Doc Ophthalmol. 2017 Jun;134(3):205-219
pubmed: 28389912
Int J Mol Sci. 2017 Sep 15;18(9):null
pubmed: 28914755
Front Pharmacol. 2018 Jan 18;8:955
pubmed: 29403374
Hippocampus. 2018 Oct;28(10):707-723
pubmed: 30067285
Invest Ophthalmol Vis Sci. 2018 Aug 1;59(10):3879-3888
pubmed: 30073348
Eur J Pharmacol. 2018 Dec 15;841:75-81
pubmed: 30326214
Exp Eye Res. 2019 Jun;183:88-97
pubmed: 30447198
Curr Opin Neurol. 2019 Feb;32(1):99-104
pubmed: 30516647
Brain Res Bull. 2019 Mar;146:171-184
pubmed: 30634016
Exp Ther Med. 2019 Jan;17(1):563-574
pubmed: 30651837
Invest Ophthalmol Vis Sci. 2019 Jan 2;60(1):365-375
pubmed: 30682206
Cell Struct Funct. 1998 Aug;23(4):201-7
pubmed: 9855113